Limits...
Cellular localization of kinin B1 receptor in the spinal cord of streptozotocin-diabetic rats with a fluorescent [Nalpha-Bodipy]-des-Arg9-bradykinin.

Talbot S, Théberge-Turmel P, Liazoghli D, Sénécal J, Gaudreau P, Couture R - J Neuroinflammation (2009)

Bottom Line: Four days post-STZ treatment, B1R expression was confirmed by quantitative real-time PCR and autoradiography.BdABK failed to displace the B2R radioligand but displaced the B1R radioligand (IC50 = 5.3 nM).In comparison, IC50 values of B1R selective antagonist R-715 and B1R agonist des-Arg9-BK were 4.3 nM and 19 nM, respectively.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Physiology, Faculty of Medicine, Université de Montréal, Succursale Downtown, Montréal, Québec, Canada. sebastien.talbot@umontreal.ca

ABSTRACT

Background: The kinin B1 receptor (B1R) is upregulated by pro-inflammatory cytokines, bacterial endotoxins and hyperglycaemia-induced oxidative stress. In animal models of diabetes, it contributes to pain polyneuropathy. This study aims at defining the cellular localization of B1R in thoracic spinal cord of type 1 diabetic rats by confocal microscopy with the use of a fluorescent agonist, [Nalpha-Bodipy]-des-Arg9-BK (BdABK) and selective antibodies.

Methods: Diabetes was induced by streptozotocin (STZ; 65 mg/kg, i.p.). Four days post-STZ treatment, B1R expression was confirmed by quantitative real-time PCR and autoradiography. The B1R selectivity of BdABK was determined by assessing its ability to displace B1R [125I]-HPP-desArg10-Hoe140 and B2R [125I]-HPP-Hoe 140 radioligands. The in vivo activity of BdABK was also evaluated on thermal hyperalgesia.

Results: B1R was increased by 18-fold (mRNA) and 2.7-fold (binding sites) in the thoracic spinal cord of STZ-treated rats when compared to control. BdABK failed to displace the B2R radioligand but displaced the B1R radioligand (IC50 = 5.3 nM). In comparison, IC50 values of B1R selective antagonist R-715 and B1R agonist des-Arg9-BK were 4.3 nM and 19 nM, respectively. Intraperitoneal BdABK and des-Arg9-BK elicited dose-dependent thermal hyperalgesia in STZ-treated rats but not in control rats. The B1R fluorescent agonist was co-localized with immunomarkers of microglia, astrocytes and sensory C fibers in the spinal cord of STZ-treated rats.

Conclusion: The induction and up-regulation of B1R in glial and sensory cells of the spinal cord in STZ-diabetic rats reinforce the idea that kinin B1R is an important target for drug development in pain processes.

Show MeSH

Related in: MedlinePlus

STZ-treated spinal cord was exposed to anti-GFAP, a specific antibody against astrocytes (A) and to BdABK (B). Colocalization between B1R and the astrocytes is shown in panel C. Anti-GFAP dye is red (ext: 550 nm/em: 570 nm) and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 7.27 μm. Pictures presented are representative of a minimum 4 sections per rat from 4 different animals.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2667487&req=5

Figure 12: STZ-treated spinal cord was exposed to anti-GFAP, a specific antibody against astrocytes (A) and to BdABK (B). Colocalization between B1R and the astrocytes is shown in panel C. Anti-GFAP dye is red (ext: 550 nm/em: 570 nm) and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 7.27 μm. Pictures presented are representative of a minimum 4 sections per rat from 4 different animals.

Mentions: Figure 12 shows the colocalization of BdABK and anti-GFAP in the spinal cord of STZ-treated rats. Data suggest that B1R is also present on spinal astrocyte cells in STZ-diabetic rats.


Cellular localization of kinin B1 receptor in the spinal cord of streptozotocin-diabetic rats with a fluorescent [Nalpha-Bodipy]-des-Arg9-bradykinin.

Talbot S, Théberge-Turmel P, Liazoghli D, Sénécal J, Gaudreau P, Couture R - J Neuroinflammation (2009)

STZ-treated spinal cord was exposed to anti-GFAP, a specific antibody against astrocytes (A) and to BdABK (B). Colocalization between B1R and the astrocytes is shown in panel C. Anti-GFAP dye is red (ext: 550 nm/em: 570 nm) and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 7.27 μm. Pictures presented are representative of a minimum 4 sections per rat from 4 different animals.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2667487&req=5

Figure 12: STZ-treated spinal cord was exposed to anti-GFAP, a specific antibody against astrocytes (A) and to BdABK (B). Colocalization between B1R and the astrocytes is shown in panel C. Anti-GFAP dye is red (ext: 550 nm/em: 570 nm) and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 7.27 μm. Pictures presented are representative of a minimum 4 sections per rat from 4 different animals.
Mentions: Figure 12 shows the colocalization of BdABK and anti-GFAP in the spinal cord of STZ-treated rats. Data suggest that B1R is also present on spinal astrocyte cells in STZ-diabetic rats.

Bottom Line: Four days post-STZ treatment, B1R expression was confirmed by quantitative real-time PCR and autoradiography.BdABK failed to displace the B2R radioligand but displaced the B1R radioligand (IC50 = 5.3 nM).In comparison, IC50 values of B1R selective antagonist R-715 and B1R agonist des-Arg9-BK were 4.3 nM and 19 nM, respectively.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Physiology, Faculty of Medicine, Université de Montréal, Succursale Downtown, Montréal, Québec, Canada. sebastien.talbot@umontreal.ca

ABSTRACT

Background: The kinin B1 receptor (B1R) is upregulated by pro-inflammatory cytokines, bacterial endotoxins and hyperglycaemia-induced oxidative stress. In animal models of diabetes, it contributes to pain polyneuropathy. This study aims at defining the cellular localization of B1R in thoracic spinal cord of type 1 diabetic rats by confocal microscopy with the use of a fluorescent agonist, [Nalpha-Bodipy]-des-Arg9-BK (BdABK) and selective antibodies.

Methods: Diabetes was induced by streptozotocin (STZ; 65 mg/kg, i.p.). Four days post-STZ treatment, B1R expression was confirmed by quantitative real-time PCR and autoradiography. The B1R selectivity of BdABK was determined by assessing its ability to displace B1R [125I]-HPP-desArg10-Hoe140 and B2R [125I]-HPP-Hoe 140 radioligands. The in vivo activity of BdABK was also evaluated on thermal hyperalgesia.

Results: B1R was increased by 18-fold (mRNA) and 2.7-fold (binding sites) in the thoracic spinal cord of STZ-treated rats when compared to control. BdABK failed to displace the B2R radioligand but displaced the B1R radioligand (IC50 = 5.3 nM). In comparison, IC50 values of B1R selective antagonist R-715 and B1R agonist des-Arg9-BK were 4.3 nM and 19 nM, respectively. Intraperitoneal BdABK and des-Arg9-BK elicited dose-dependent thermal hyperalgesia in STZ-treated rats but not in control rats. The B1R fluorescent agonist was co-localized with immunomarkers of microglia, astrocytes and sensory C fibers in the spinal cord of STZ-treated rats.

Conclusion: The induction and up-regulation of B1R in glial and sensory cells of the spinal cord in STZ-diabetic rats reinforce the idea that kinin B1R is an important target for drug development in pain processes.

Show MeSH
Related in: MedlinePlus